Metastatic ovarian cancer drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor accelerating the demand for these drugs include the growing prevalence of metastatic ovarian cancer. Ovarian cancer is the second most common gynecologic cancer in the US. The American Cancer Society (ACS) estimates that there will be nearly 19,880 women receiving a new diagnosis of ovarian cancer in the US. The current research in ovarian cancer is focused on using novel treatments such as immunotherapy, targeted therapy, and most importantly combination regimens. Immuno-oncologic agents have shown promising results with improved survival and lower toxicity. However, a single-agent response rate of PD-1/ PD-L1 molecules such as Opdivo and Keytruda for ovarian cancer treatment is less than 20.0%.
Combination therapies, specifically those including checkpoint inhibitors, are poised to be introduced in the first-line setting to target major unmet needs including overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life. The need for more effective treatment options is another factor that is fueling the growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. The development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treatment of metastatic ovarian cancer.
To Request a Sample of our Report on Metastatic Ovarian Cancer Drug Market: https://www.omrglobal.com/request-sample/metastatic-ovarian-cancer-drug-market
Market Coverage
- The market number available for – 2022-2029
- Base year- 2022
- Forecast period- 2023-2029
Segment Covered-
- By Product Type
- By Application
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: F. Hoffman La-Roche AG, Pfizer Inc., and Eisai Co., Ltd., among others.
Metastatic Ovarian Cancer Drug Market Report by Segment
By Product Type
- E-7449
- Crizotinib
- CMB-305
- G-305
- LV-305
- Others
By Application
- Hospital
- Clinic
- Others
A full Report of Metastatic Ovarian Cancer Drug Market is Available @ https://www.omrglobal.com/industry-reports/metastatic-ovarian-cancer-drug-market
Metastatic Ovarian Cancer Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/metastatic-ovarian-cancer-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
